DEA’s long-awaited rescheduling decision opens chances for cannabis research


By Nat Stein This news isn’t clearly good or bad for state-legal patients, consumers, businesses, growers, regulators and government officials. When the “first half of 2016” came and went without a marijuana rescheduling announcement, it became clear the Drug Enforcement Agency didn’t feel overly obligated to meet its own self-imposed …

Continue reading